Shoulder1.com: Great Information, Real Community, Better Living.
 Register
 Login
 Main Page
 Shoulder News
Feature Story
Shoulder Technology
Real Life Recoveries
 Education Center
Conditions
Procedures
 Shoulder  Hero™
Dr. Evan Flatow:
Innovating Shoulder Surgery
About Heroes
 Join the Discussion in  Our Forums
 Community
Shoulder1 Forums
Patient Stories
Shoulder Journals
 Reference
Ask an Expert
FAQ's
Locate a Doctor
Reference Library
Anatomy
Video Library
 Bookmark Us
 
advertisement
Search the Body1 Network
September 25, 2017  
SHOULDER NEWS: Feature Story

  • Print this Article
  • Email this Article
  • Links/Reprints
  • New Drug Shows Promise Against Arthritis

    New Drug Shows Promise Against Arthritis


    November 12, 2003

    An experimental new drug designed to shut down the body's misguided assault on its own joints is showing promise against rheumatoid arthritis, relieving its crippling effects with few if any side effects.

    The drug, still in testing, neutralizes the immune system T cells that help direct the assault.

    It could give doctors another weapon in their arsenal of drugs against rheumatoid arthritis, which afflicts 2.1 million Americans.

    Other drugs target some of the processes that underlie rheumatoid arthritis, but this is the first to attack the disease in precisely this way.

    In a study of 339 patients, CTLA4Ig was added to methotrexate - the standard drug - in arthritis sufferers who had not gotten enough relief from methotrexate and still had many swollen and painful joints.

    After six months, 60 percent of these patients were feeling better - some of them dramatically so. Only 35 percent of the patients on methotrexate alone reported some relief.

    "I'm very excited about it. But there's still a considerable amount of work to be done," said Dr. Gary Firestein, chief of rheumatology, allergy and immunology at the University of California at San Diego and chairman of the Food and Drug Administration's arthritis advisory committee.

    Bristol-Myers Squibb Co. said it expects to apply to the FDA some time next year for approval to sell the drug.

    More than 2,000 patients are taking part in the final round of tests needed to win FDA approval.

    The findings were published in Thursday's New England Journal of Medicine. The study was led by Dr. Joel M. Kremer, director of research at the Center for Rheumatology in Albany, N.Y., and clinical professor of medicine at Albany Medical College.

    The drug cannot be taken by mouth; it must be given by an intravenous infusion. In the study, it was given three times in one month, then once every month after that for five months. People who received it with methotrexate had no more side effects than those who got only methotrexate.

    CTLA4Ig is one of many drugs on the market or in development that take advantage of scientists' clearer understanding of the complicated processes of inflammation and autoimmune diseases. Different drugs take aim at different parts of the process.

    TNF inhibitors, for example, target an inflammation-causing protein called tumor necrosis factor, or TNF.

    Methotrexate, originally developed to fight cancer, replaced gold salts - which helped fewer than one-third of all patients - as the standard drug against rheumatoid arthritis in the late 1980s. But two-thirds of all patients still hurt. TNF inhibitors have helped some of them.

    Firestein said there is a good chance that people who do not respond to TNF inhibitors will respond to the new drug.

    "Each time, the slice of the pie of people who do not respond gets thinner and thinner," he said.

    ---=

    http://nejm.org

    Arthritis Foundation: http://www.arthritis.org

    American College of Rheumatology: www.rheumatology.org


    Last updated: 12-Nov-03

    Comments

  • Add Comment
  •    
    Interact on Shoulder1

    Discuss this topic with others.
     
    Feature Archives

    Protein Appears to Protect Against Bone Loss in Arthritis

    Risk Factors Identified for Little League Shoulder

    Orthopedic outcomes affected by activity level

    Understanding the Full Impact of Treatments is Important for Patients with Rotator Cuff Injury

    Joint Replacement Surgery Could Become A Thing Of The Past With New Theory On Genesis Of Osteoarthritis

    Next 5 Features ...

    More Features ...
       
     
    Related Multimedia

    Interview with Dr. Andrews

    More Features ...
     
    Related Content
    Outlook Improves for Rheumatoid Arthritis Patients

    Healthy Diet = Healthy Joints

    Fewer Hospitalizations for Rheumatoid Arthritis

    FDA Says Remicade Users Suffer Ailments

    Rheumatoid Arthritis

    More Features ...
     
    Home About Us Press Jobs Advertise With Us Contact Us
    advertisement
    © 2017 Body1 All rights reserved.
    Disclaimer: The information provided within this website is for educational purposes only and is not a substitute for consultation with your physician or healthcare provider. The opinions expressed herein are not necessarily those of the Owners and Sponsors of this site. By using this site you agree to indemnify, and hold the Owners and Sponsors harmless, from any disputes arising from content posted here-in.